Blue Jet Healthcare has recently experienced a change in its evaluation, reflecting strong financial performance, particularly in Q4 FY24-25, with significant profit growth. The company has outperformed the broader market over the past year and maintains a strong market position, despite some long-term growth concerns.
Q3 FY25 Financial Highlights
Revenue: ₹3,183.82 million, marking a 91% year-on-year (YoY) increase and a 53% quarter-on-quarter (QoQ) growth.
Net Profit: ₹989.83 million, up 208.4% YoY and 69.6% QoQ.
EBITDA: ₹1,324.94 million, reflecting a 147.9% YoY rise.
EBITDA Margin: Expanded by 630 basis points to 39.0%.
Earnings Per Share (EPS): ₹5.71, compared to ₹1.85 in Q3 FY24.
Strategic Initiatives and Market Position
R&D Investment: The company announced a ₹40 crore investment to establish a dedicated Research & Development facility, aiming to bolster innovation in Active Pharmaceutical Ingredients (APIs) and pharma intermediates .
Market Performance: Blue Jet Healthcare's stock achieved a new 52-week high of ₹954, reflecting strong investor confidence and a significant market capitalization of ₹16,123 crore
SOURCE-Marketsmojo
#FinancialPerformance #QuarterlyResults #StockMarket
#MarketOutperformance #PharmaStocks #HealthcareNews
Q3 FY25 Financial Highlights
Revenue: ₹3,183.82 million, marking a 91% year-on-year (YoY) increase and a 53% quarter-on-quarter (QoQ) growth.
Net Profit: ₹989.83 million, up 208.4% YoY and 69.6% QoQ.
EBITDA: ₹1,324.94 million, reflecting a 147.9% YoY rise.
EBITDA Margin: Expanded by 630 basis points to 39.0%.
Earnings Per Share (EPS): ₹5.71, compared to ₹1.85 in Q3 FY24.
Strategic Initiatives and Market Position
R&D Investment: The company announced a ₹40 crore investment to establish a dedicated Research & Development facility, aiming to bolster innovation in Active Pharmaceutical Ingredients (APIs) and pharma intermediates .
Market Performance: Blue Jet Healthcare's stock achieved a new 52-week high of ₹954, reflecting strong investor confidence and a significant market capitalization of ₹16,123 crore
SOURCE-Marketsmojo
#FinancialPerformance #QuarterlyResults #StockMarket
#MarketOutperformance #PharmaStocks #HealthcareNews
Blue Jet Healthcare has recently experienced a change in its evaluation, reflecting strong financial performance, particularly in Q4 FY24-25, with significant profit growth. The company has outperformed the broader market over the past year and maintains a strong market position, despite some long-term growth concerns.
Q3 FY25 Financial Highlights
Revenue: ₹3,183.82 million, marking a 91% year-on-year (YoY) increase and a 53% quarter-on-quarter (QoQ) growth.
Net Profit: ₹989.83 million, up 208.4% YoY and 69.6% QoQ.
EBITDA: ₹1,324.94 million, reflecting a 147.9% YoY rise.
EBITDA Margin: Expanded by 630 basis points to 39.0%.
Earnings Per Share (EPS): ₹5.71, compared to ₹1.85 in Q3 FY24.
Strategic Initiatives and Market Position
R&D Investment: The company announced a ₹40 crore investment to establish a dedicated Research & Development facility, aiming to bolster innovation in Active Pharmaceutical Ingredients (APIs) and pharma intermediates .
Market Performance: Blue Jet Healthcare's stock achieved a new 52-week high of ₹954, reflecting strong investor confidence and a significant market capitalization of ₹16,123 crore
SOURCE-Marketsmojo
#FinancialPerformance #QuarterlyResults #StockMarket
#MarketOutperformance #PharmaStocks #HealthcareNews
